Joseph A. Kozlowski

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

33h-index3.9kcitations134works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(30), HIV/AIDS drug development and treatment(29), Monoclonal and Polyclonal Antibodies Research(16), Receptor Mechanisms and Signaling(14), Cannabis and Cannabinoid Research(13)

Publications134 total

Rapid Affinity and Microsomal Stability Ranking of Crude Mixture Libraries of Histone Deacetylase Inhibitors
ACS Medicinal Chemistry Letters·2024· 5 citedOpen Access
Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation
Bioorganic & Medicinal Chemistry Letters·2021· 9 citedOpen Access
Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity
Journal of Medicinal Chemistry·2021· 21 citedOpen Access
Synthesis of HDAC Inhibitor Libraries via Microscale Workflow
ACS Medicinal Chemistry Letters·2021· 18 citedOpen Access
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group
ACS Medicinal Chemistry Letters·2020· 52 citedOpen Access
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
Bioorganic & Medicinal Chemistry Letters·2020· 16 citedOpen Access
Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir
Bioorganic & Medicinal Chemistry Letters·2020· 22 citedOpen Access
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance
ACS Medicinal Chemistry Letters·2020· 27 citedOpen Access
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation
Bioorganic & Medicinal Chemistry Letters·2020· 26 citedOpen Access
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core
Bioorganic & Medicinal Chemistry Letters·2019· 5 citedOpen Access
Building a Culture of Health and Well-Being at Merck
Population Health Management·2018· 16 citedOpen Access
<i>In Vitro</i> Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A
Antimicrobial Agents and Chemotherapy·2018· 6 citedOpen Access
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions
Journal of Medicinal Chemistry·2018· 13 cited
MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV
Bioorganic & Medicinal Chemistry Letters·2018· 10 citedOpen Access
Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections
ACS symposium series·2018
A Novel Histone Deacetylase (HDAC) Inhibitor Attenuates Cardiac Dysfunction in the Setting of Pressure Overload Heart Failure
Journal of Molecular and Cellular Cardiology·2017· 1 cited
Development of a prodrug of hydantoin based TACE inhibitor
Bioorganic & Medicinal Chemistry Letters·2017· 7 citedOpen Access
Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors
Bioorganic & Medicinal Chemistry Letters·2017· 9 citedOpen Access
Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis
Bioorganic & Medicinal Chemistry Letters·2017· 13 citedOpen Access
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms
Journal of Medicinal Chemistry·2016· 47 cited
page 1 of 7Next →

Frequent Co-authors

Bruce H. Lipshutz(13), Brian J. Lavey(13), Daniel Lundell(13), Stuart B. Rosenblum(9), Guowei Zhou(9), Wensheng Yu(9), Neng‐Yang Shih(8), Robert S. Wilhelm(7), Jay S. Fine(7), Waldemar Gonsiorek(6), G. Anilkumar(6), Zhuyan Guo(6), Peter Orth(6), Xiaoda Niu(6), John J. Piwinski(6), Ling Tong(6), Oleg Selyutin(6), Sony Agrawal(6), Charles A. Lunn(5), R. William Hipkin(5)